www.cnbc.com/2026/08/05/b... Bank of America is spending more than $250 million annually to provide GLP-1 weight loss medications to its workforce. Citing potential near-and long-term health benefits for employees, such as reduced incidents of heart issues, as key drivers for absorbing the costs.
Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says
Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.
cnbc.com